Your browser is no longer supported. Please, upgrade your browser.
Bio-Techne Corporation
Index- P/E102.22 EPS (ttm)4.59 Insider Own0.50% Shs Outstand38.86M Perf Week4.38%
Market Cap17.88B Forward P/E62.04 EPS next Y7.56 Insider Trans-34.72% Shs Float38.66M Perf Month6.18%
Income184.10M PEG6.81 EPS next Q1.70 Inst Own95.50% Short Float1.13% Perf Quarter10.73%
Sales847.80M P/S21.09 EPS this Y135.60% Inst Trans0.23% Short Ratio1.73 Perf Half Y31.91%
Book/sh39.62 P/B11.84 EPS next Y16.91% ROA8.90% Target Price457.22 Perf Year70.04%
Cash/sh7.25 P/C64.74 EPS next 5Y15.00% ROE12.50% 52W Range228.66 - 470.97 Perf YTD47.75%
Dividend1.28 P/FCF102.12 EPS past 5Y15.00% ROI6.30% 52W High0.50% Beta1.14
Dividend %0.27% Quick Ratio3.30 Sales past 5Y10.30% Gross Margin67.30% 52W Low107.00% ATR11.60
Employees2300 Current Ratio4.10 Sales Q/Q25.10% Oper. Margin24.50% RSI (14)64.11 Volatility2.52% 2.44%
OptionableYes Debt/Eq0.14 EPS Q/Q21.80% Profit Margin21.70% Rel Volume0.29 Prev Close469.18
ShortableYes LT Debt/Eq0.13 EarningsAug 05 BMO Payout26.80% Avg Volume253.01K Price473.35
Recom1.80 SMA204.25% SMA508.99% SMA20028.91% Volume51,861 Change0.89%
Mar-08-21Upgrade Stephens Equal-Weight → Overweight $380 → $425
Feb-23-21Upgrade Stifel Hold → Buy $435
Jan-25-21Reiterated The Benchmark Company Buy $320 → $410
Nov-10-20Initiated KeyBanc Capital Markets Sector Weight $340
Sep-30-20Initiated Atlantic Equities Overweight $365
Jul-15-20Downgrade Stephens Overweight → Equal-Weight
May-27-20Downgrade Stifel Buy → Hold $245 → $260
May-14-20Initiated The Benchmark Company Buy $290
Jan-08-20Resumed Stephens Overweight $250
Jan-08-20Initiated Wells Fargo Equal Weight $230
Jan-07-20Initiated Citigroup Neutral $235
Nov-15-19Initiated Stifel Buy
Jul-02-19Upgrade Janney Neutral → Buy $200 → $270
Jan-14-19Upgrade Stephens Equal-Weight → Overweight
Oct-31-18Downgrade Craig Hallum Buy → Hold
Oct-17-18Initiated Goldman Neutral $190
Jun-15-18Initiated Argus Buy $185
Jul-13-17Initiated Wells Fargo Market Perform
Feb-09-17Initiated Citigroup Buy $115
Jan-18-17Initiated Deutsche Bank Buy $115
Jul-20-21 12:01AM  
Jul-15-21 07:00AM  
Jul-13-21 07:00AM  
Jun-28-21 07:00AM  
Jun-24-21 07:00AM  
Jun-22-21 04:49AM  
Jun-15-21 07:00AM  
Jun-14-21 08:17AM  
Jun-10-21 07:00AM  
Jun-08-21 07:00AM  
Jun-07-21 04:55PM  
Jun-02-21 11:34AM  
May-24-21 09:15AM  
May-19-21 07:00AM  
May-18-21 07:00AM  
May-13-21 12:29PM  
May-10-21 07:00AM  
May-07-21 01:31AM  
May-06-21 07:15AM  
May-04-21 02:20PM  
Apr-27-21 07:00AM  
Apr-26-21 01:39AM  
Apr-23-21 06:37AM  
Apr-22-21 01:37PM  
Apr-19-21 12:53PM  
Apr-15-21 07:49AM  
Apr-14-21 07:00AM  
Apr-08-21 07:00AM  
Apr-06-21 04:01PM  
Mar-29-21 07:00AM  
Mar-26-21 07:00AM  
Mar-23-21 07:00AM  
Mar-15-21 07:00AM  
Mar-11-21 12:54PM  
Mar-10-21 10:31AM  
Mar-08-21 07:00AM  
Mar-04-21 08:12AM  
Mar-03-21 04:45PM  
Mar-02-21 07:00AM  
Mar-01-21 07:00AM  
Feb-23-21 07:00AM  
Feb-22-21 06:53AM  
Feb-18-21 01:15PM  
Feb-16-21 07:00AM  
Feb-11-21 07:00AM  
Feb-10-21 11:31AM  
Feb-08-21 07:30AM  
Feb-03-21 01:00PM  
Feb-02-21 03:30PM  
Jan-30-21 01:19PM  
Jan-28-21 07:00AM  
Jan-14-21 07:00AM  
Jan-08-21 06:54AM  
Dec-21-20 10:03AM  
Dec-09-20 03:44AM  
Dec-08-20 12:28PM  
Dec-02-20 07:00AM  
Nov-25-20 07:30AM  
Nov-11-20 07:00AM  
Nov-09-20 10:38AM  
Nov-05-20 10:01PM  
Nov-04-20 07:00AM  
Nov-02-20 07:00AM  
Oct-28-20 07:30AM  
Oct-26-20 07:30AM  
Oct-19-20 07:00AM  
Oct-15-20 07:00AM  
Oct-13-20 09:37AM  
Oct-01-20 07:00AM  
Sep-30-20 07:00AM  
Sep-28-20 08:36PM  
Sep-23-20 07:00AM  
Sep-22-20 07:00AM  
Sep-21-20 07:00AM  
Sep-17-20 07:00AM  
Sep-15-20 03:41PM  
Sep-11-20 02:57PM  
Sep-08-20 07:00AM  
Sep-03-20 07:00AM  
Aug-19-20 08:00AM  
Aug-11-20 07:00AM  
Aug-06-20 06:00AM  
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hippel JamesChief Financial OfficerJul 12Option Exercise106.5910,0001,065,90019,137Jul 14 04:57 PM
Hippel JamesChief Financial OfficerJul 12Sale456.6710,0004,566,6639,137Jul 14 04:57 PM
Kummeth Charles R.Chief Executive OfficerJun 18Sale449.232,9091,306,820154,406Jun 21 04:36 PM
Kummeth Charles R.Chief Executive OfficerJun 17Sale449.819,5894,313,186157,315Jun 21 04:36 PM
Kummeth Charles R.Chief Executive OfficerJun 14Sale449.157,4813,360,066166,904Jun 16 07:22 PM
Kelderman KimPres. Diagnostics & GenomJun 09Sale433.00811351,1630Jun 11 04:59 PM
Hippel JamesChief Financial OfficerJun 07Option Exercise106.599,9421,059,71819,079Jun 09 04:48 PM
Hippel JamesChief Financial OfficerJun 07Sale421.939,9424,194,8319,137Jun 09 04:48 PM
Kummeth Charles R.Chief Executive OfficerMay 25Option Exercise94.3536,8493,476,703195,690May 27 04:25 PM
Kelderman KimPres. Diagnostics & GenomMay 25Sale424.00845358,280811May 27 04:26 PM
Kummeth Charles R.Chief Executive OfficerFeb 16Option Exercise94.3530,0002,830,500176,269Feb 18 04:38 PM
Furlow Brenda S.SVP - General CounselFeb 12Option Exercise106.5910,0001,065,90016,124Feb 17 04:42 PM
Hippel JamesChief Financial OfficerFeb 12Option Exercise106.5910,0001,065,90019,137Feb 17 04:46 PM
Furlow Brenda S.SVP - General CounselFeb 12Sale398.6410,0003,986,3526,124Feb 17 04:42 PM
Hippel JamesChief Financial OfficerFeb 12Sale400.3910,0004,003,9089,137Feb 17 04:46 PM
Nusse RoelandDirectorFeb 08Option Exercise67.476,000404,85012,765Feb 10 04:26 PM
Nusse RoelandDirectorFeb 08Sale385.086,0002,310,4816,765Feb 10 04:26 PM
Eansor Norman DavidPresident-Protein SciencesFeb 05Option Exercise106.5932,9333,510,32834,251Feb 09 05:24 PM
Kelderman KimPres. Diagnostics & GenomFeb 05Sale388.45823319,694845Feb 09 06:31 PM
Eansor Norman DavidPresident-Protein SciencesFeb 05Sale380.6832,93312,537,0231,318Feb 09 05:24 PM
Kummeth Charles R.Chief Executive OfficerJan 15Sale344.0020,0006,880,000146,269Jan 20 04:42 PM
Hippel JamesChief Financial OfficerJan 11Option Exercise106.5910,0001,065,90019,137Jan 13 05:18 PM
Hippel JamesChief Financial OfficerJan 11Sale333.6310,0003,336,3229,137Jan 13 05:18 PM
Kummeth Charles R.Chief Executive OfficerDec 07Sale308.005,0001,540,000166,269Dec 09 04:28 PM
Furlow Brenda S.SVP - General CounselNov 30Option Exercise106.5911,7951,257,22916,981Dec 02 06:01 PM
Furlow Brenda S.SVP - General CounselNov 30Sale301.9410,8573,278,1266,124Dec 02 06:01 PM
BAUMGARTNER ROBERT VDirectorNov 18Option Exercise66.905,000334,50014,612Nov 20 04:29 PM
BAUMGARTNER ROBERT VDirectorNov 18Sale303.335,0001,516,6759,612Nov 20 04:29 PM
Hippel JamesChief Financial OfficerNov 11Option Exercise106.597,391787,80716,528Nov 12 06:59 PM
Hippel JamesChief Financial OfficerNov 11Sale307.057,3912,269,4299,137Nov 12 06:59 PM
Seth AlpnaDirectorNov 09Option Exercise145.755,023732,1187,162Nov 19 12:27 PM
Hippel JamesChief Financial OfficerNov 09Option Exercise106.593,600383,72412,737Nov 12 06:59 PM
Hippel JamesChief Financial OfficerNov 09Sale309.793,6001,115,2519,137Nov 12 06:59 PM
Seth AlpnaDirectorNov 09Sale306.625,0231,540,1672,139Nov 19 12:27 PM
HIGGINS JOHN LDirectorNov 06Option Exercise70.355,000351,7509,412Nov 10 04:53 PM
STEER RANDOLPH CDirectorNov 06Option Exercise68.6210,000686,25015,112Nov 10 06:00 PM
Kummeth Charles R.Chief Executive OfficerNov 06Option Exercise86.2525,1572,169,791186,644Nov 10 06:04 PM
STEER RANDOLPH CDirectorNov 06Sale301.9910,0003,019,9485,112Nov 10 06:00 PM
HIGGINS JOHN LDirectorNov 06Sale300.355,0001,501,7444,412Nov 10 04:53 PM
Hippel JamesChief Financial OfficerNov 05Option Exercise108.498,809955,68817,946Nov 06 04:47 PM
Hippel JamesChief Financial OfficerNov 05Sale286.128,8092,520,4579,137Nov 06 04:47 PM
Hippel JamesChief Financial OfficerNov 04Option Exercise108.497,100770,27916,237Nov 06 04:47 PM
Hippel JamesChief Financial OfficerNov 04Sale274.007,1001,945,4279,137Nov 06 04:47 PM
Eansor Norman DavidPresident-Protein SciencesAug 09Option Exercise0.002,17402,174Aug 11 06:21 PM
Furlow Brenda S.SVP - General CounselAug 09Option Exercise0.001,72406,035Aug 11 06:22 PM
Kummeth Charles R.Chief Executive OfficerAug 09Option Exercise0.0021,2910173,774Aug 11 06:20 PM
Hippel JamesChief Financial OfficerAug 09Option Exercise0.004,438011,321Aug 11 06:21 PM